Trinity Biotech plc
9.90%
1,463,058,248
888721
896438504
Jan 21, 2026
Jan 26, 2026, 05:19 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 9.90% | 1,463,058,248 | 0 | 1,463,058,248 |
| Perceptive Credit Advisors LLC | Investment Adviser | 9.90% | 1,463,058,248 | 0 | 1,463,058,248 |
| Joseph Edelman | Individual | 9.90% | 1,463,058,248 | 0 | 1,463,058,248 |
| Perceptive Credit Holdings II, L.P. | Partnership | 9.90% | 243,009,708 | 0 | 243,009,708 |
| Perceptive Credit Holdings III, L.P. | Partnership | 9.90% | 1,220,048,540 | 0 | 1,220,048,540 |
Disclosure Items (2)
Class A Ordinary Shares, $0.0001 par value per share
Trinity Biotech plc
IDA Business Park, Bray, Co. Wicklow, L2, A98 H5C8
Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows: The information set forth in the cover pages to this Amendment No. 7 to the Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 374,206,640 Ordinary Shares outstanding, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on January 23, 2026, and assumes the exercise of all Warrants and the conversion of the Convertible Note, the Milestone Payment Obligation and the Contingent Payment Obligation to the extent permitted by the Beneficial Ownership Cap.
The information set forth in Item 5(a) is incorporated herein by reference.
Except as set forth on Schedule A, no Reporting Person has effected any transaction in shares of Ordinary Shares since the filing of Amendment No. 6 to the Schedule 13D, filed with the Securities and Exchange Commission on December 23, 2025.